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Abstract
Background: Leukemia inhibitory factor (LIF) is known to inhibit myogenic differentiation as well as to inhibit
apoptosis and caspase-3 activation in non-differentiating myoblasts. In addition caspase-3 activity is required for
myogenic differentiation. Therefore the aim of this study was to further investigate mechanisms of the differentiation
suppressing effect of LIF in particular the possibility of a caspase-3 mediated inhibition of differentiation.
Results: LIF dependent inhibition of differentiation appeared to involve several mechanisms. Differentiating
myoblasts that were exposed to LIF displayed increased transcripts for c-fos. Transcripts for the cell cycle inhibitor
p21 as well as muscle regulatory factors myoD and myogenin were decreased with LIF exposure. However, LIF did
not directly induce a proliferative effect under differentiation conditions, but did prevent the proportion of
myoblasts that were proliferating from decreasing as differentiation proceeded. LIF stimulation decreased the
percentage of cells positive for active caspase-3 occurring during differentiation. Both the effect of LIF inhibiting
caspase-3 activation and differentiation appeared dependent on mitogen activated protein kinase and extracellular
signal regulated kinase kinase (MEK) signalling. The role of LIF in myogenic differentiation was further refined to
demonstrate that myoblasts are unlikely to secrete LIF endogenously.
Conclusions: Altogether this study provides a more comprehensive view of the role of LIF in myogenic
differentiation including LIF and receptor regulation in myoblasts and myotubes, mechanisms of inhibition of
differentiation and the link between caspase-3 activation, apoptosis and myogenic differentiation.
Background
Myogenic differentiation is a critical process for the devel-
opment and homeostasis of muscle tissue. Myogenesis, the
formation of muscle cell syncytia, occurs during embryo-
nic development and in cases of muscle injury. When
myofibers are damaged by stimuli such as mechanical
stress, or loss of neurotrophic support, they regenerate by
activation and proliferation of the normally quiescent resi-
dent satellite cell population [1]. Proliferating satellite
cells, termed myoblasts, subsequently differentiate and
fuse to create myotubes which can mature into functional
myofibers. These mono-nucleated muscle progenitor cells
differentiate by inducing the transcriptional activity of
basic-helix-loop-helix transcription factors such as myoD
and myogenin [2,3]. Commonly called muscle regulator
factors (MRFs), these transcription factors initiate irrever-
sible cell cycle arrest via increasing expression of p21 [4],
which subsequently inhibits cyclin dependent kinase-2
(cdk-2) activity preventing cell cycle progression [5]. Myo-
blast cell membranes then fuse to create multinucleated
syncytial cells known as myotubes [6]. Whilst these post-
mitotic syncytia are resistant to apoptosis, up until the
point of increased expression of cdk inhibitors such as p21
during differentiation, myoblasts are susceptible to apopto-
sis [7]. The process of myogenic differentiation is asso-
ciated with typical apoptotic signalling such as caspase-3
activation, not only coinciding with differentiation but
necessary for progression of differentiation [8]. Although
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any medium, provided the original work is properly cited.differentiation associated apoptotic signalling may contri-
bute positively to myogenic differentiation, it may also
negatively lead to erroneous cell death [9]. Various pro-
teins including growth factors and cytokines can regulate
myogenic differentiation. One such cytokine, which shows
increased expression in injured muscle undergoing
myogenesis, is leukemia inhibitory factor (LIF) [10].
LIF conforms to the gp130 signalling of interleukin-6
family cytokines and is shown to inhibit differentiation
of myoblasts [11]. LIF binds to a heterodimer of gp130
and the LIF receptor (LIFR) [12], which can lead to acti-
vation of a number of signalling pathways. These
include signal transducer and activator of transcription
3 (STAT3), phosphotidylinositol-3 kinase (PI3K) and
mitogen activated protein kinase kinase (MEK) [13]. LIF
also inhibits caspase-3 activation and DNA fragmenta-
tion of myoblasts caused by induction of apoptosis with
staurosporine [14]. Inhibition of myoblast differentiation
by LIF is shown to be dependent on MEK signalling and
independent of STAT3, while inhibition of staurosporine
induced apoptosis was PI3K dependent [14]. Given the
association between myogenic differentiation and apop-
totic signalling and the involvement of LIF in both these
processes separately we thought it prudent to determine
if LIF influences differentiation-associated apoptotic sig-
nalling and to examine the mechanisms responsible for
inhibition of myogenic differentiation by LIF.
LIF has been shown to play a role and display increased
expression in regenerating muscle tissue [10,15]. This is
comprised of numerous cell types including but not lim-
ited to neurons, fibroblasts and macrophages as well as
myoblasts. However little is known about the expression
and function of endogenous LIF during myoblast differ-
entiation alone despite inhibition by exogenous LIF. We
therefore set out to examine the regulation and function
of endogenous LIF by myoblasts as well as to investigate
mechanisms of inhibition of differentiation by LIF.
Herein we describe the inhibition of myogenic differen-
tiation of myoblasts by LIF and show that this effect is
mediated by inhibition of caspase-3 activation, down-
regulation of myogenic transcription factors myoD
and myogenin and cell cycle inhibitor p21 whilst up-
regulating the immediate early gene c-fos.
Results
Exogenous LIF delays myoblast differentiation and
myotube formation
A visual comparison of cultures incubated with 10 ng/mL
LIF compared to untreated controls showed that
24 hours after differentiation was induced there appeared
to be qualitatively less myotubes present in the LIF-
treated compared to control cultures (Figure 1A). From
48 hours and onwards myotube formation appeared to
have reached a maximum and there was no discernible
difference in the size, amount or density of myotubes
present with LIF treatment. Creatine kinase (CK) enzy-
matic activity increases over time as myoblasts differenti-
ate and persists in fused myotubes [16]. Thus we used
CK activity as a measure of the effect of exogenous LIF
administration on C2C12 myoblasts differentiation. CK
activity increased in control cultures induced to differ-
entiate up to a maximum of 48 hours similar to myotube
Figure 1 LIF inhibits myotube formation and differentiation
measured by creatine kinase activity. (A) Phase contrast images of
myoblast cultures either with or without 10 ng/mL LIF treatment at 0,
24 and 48 hours after induction of differentiation showed
qualitatively less myotubes present at 24 hours of differentiation with
LIF treatment. (B) Creatine kinase activity of myogenic cultures is
decreased with 10 ng/mL LIF treatment at 12 and 24 but not 48 and
72 hours following the induction of differentiation. Asterisk (*)
indicates P < 0.05 for LIF-treated compared to control by Student’s
t-test at that time (n = 4). (C) At 24 hours of differentiation, inhibition
of creatine kinase activity with increasing concentrations of LIF, up to
a maximum effect with 10 ng/mL LIF, was observed (n = 4).
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cantly decreased this compared to control at the time
points of 12 and 24 hours prior but not 48 hours or later
(Figure 1B). This decrease at 24 hours (t = 24) caused by
LIF treatment was dose dependent with concentrations
of LIF 10 ng/mL and greater inducing a maximum inhibi-
tory effect representing a 30% reduction from control
values (Figure 1C). Overall these results indicate that LIF
may slow the rate of differentiation of myoblasts, but
does not prevent myoblasts from reaching the same end-
point of differentiation and myotube formation.
LIF treatment inhibits differentiation associated apoptotic
signalling and DNA fragmentation
The number of myoblasts positive for the active cleaved
caspase-3 (as a proportion of total cells) increased
following induction of differentiation. Not all active
caspase-3 positive myoblasts appeared apoptotic in mor-
phology, suggesting that caspase-3 activation may not
represent signalling towards apoptotic cell death but
rather may relate to signalling of myogenic differentia-
tion. Caspase-3 activation was greatest 24 hours after dif-
ferentiation and had subsided to basal levels by 48 hours
when maximum differentiation and myotube formation
was observed (Figure 2A). Percentages of cells positive
for active caspase-3 were lower in LIF-treated cultures at
24 hours but not at 48 hours, temporally consistent with
when the effect of LIF on myotube formation and differ-
entiation was observed (Figure 1). Pharmacological inhi-
bitors of MEK and PI3K signalling pathways along with
dual staining of active caspase-3 and myosin heavy chain
(MYHC, a marker of differentiated myoblasts) was used
Figure 2 LIF inhibits activation of caspase-3 and DNA fragmentation during differentiation. (A) Representative immunofluorescent images
of 10 ng/mL LIF-treated and control cultures labelled for cleaved caspase-3 (green) and DNA with DAPI (blue). A cleaved caspase-3 positive
myoblast with more typical apoptotic morphology with condensed chromatin and small cytoplasmic space is indicated with a thick arrow. A
cleaved caspase-3 positive myoblast with normal fusiform morphology is indicated with a thin arrow. Scale bar is 100 μm. (B) Cultures
differentiated for 24 hours and immunofluorescently stained for cleaved caspase-3 and MYHC simultaneously were counted and the percentages
of cleaved caspase-3 positive nuclei (of total nuclei) and fusion index (percentage of nuclei contained within MYHC positive syncytia)
represented graphically. -/+ indicates either the absence or presence of LIF (10 ng/mL), wortmannin (WORT; 100 nM), U0126 (10 μM) or DMSO
(0.1% (v/v) in media as the vehicle for wortmannin and U0126) treatment. Asterisk (*) indicates P < 0.05 and ns indicates P > 0.05 with one-way
ANOVA and Dunnet’s post-hoc test for all treatments compared to control (n = 4). (C) After 24 hours of differentiation cultures were TUNEL
stained and the percentage of total cells positive for TUNEL represented graphically. Asterisk (*) indicates P < 0.05 for LIF-treated compared to
control with Student’s t-test (n = 4).
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tionship between LIF, caspase-3 activation, differentiation
and the signalling pathways involved. At this 24 hour
time point LIF treatment alone reduced the percentage
of cells positive for active caspase-3 by 50% and reduced
the fusion index (the number of nuclei contained within
MYHC positive syncytia as a percentage of total) by 64%
compared to control (Figure 2B). The effects of LIF on
caspase-3 activation and fusion index were not prevented
by inhibition of the PI3K pathway with wortmannin. In
fact, wortmannin alone significantly decreased the fusion
index. Inhibition of MEK signalling with U0126 in the
presence of LIF restored caspase-3 activation and fusion
index to levels that were not significantly different from
control, suggesting that the caspase-3 activation and dif-
ferentiation are intertwined and are both inhibited by LIF
through activation of MEK signalling. TUNEL positive
cells were observed, with the highest levels (2% of total)
24 hours after induction of differentiation. This was con-
sistent with the time course of caspase-3 activation. At
this time point LIF treatment also decreased the percen-
tage of TUNEL positive cells by 60% compared to control
(Figure 2C).
Caspase-3 inhibition blocks myogenic differentiation but
is not additive with LIF
A small peptide Ac-DEVD-CHO, which mimics the sub-
strate recognition sequence for caspase-3, reversibly
binds to the active site of cleaved caspase-3 and inhibits
the proteolytic activity, was utilized to discern whether
caspase-3 inhibition blocks myogenic differentiation to
the same degree as LIF and if inhibition of LIF and cas-
pase-3 would be additive. Myoblasts were incubated
with or without 10 ng/mL LIF and 100 μMA c - D E V D -
CHO prior to differentiation as described and after
24 hours of culture in differentiation media lysed for a
colorimetric assay of caspase-3 proteolytic activity and
CK activity. Assay of undifferentiated controls indicated
that caspase-3 activity increased as differentiation pro-
ceeded similar to the immunocytochemical detection
method (results not shown). Phase contrast images of
differentiated cultures suggested that both LIF and
Ac-DEVD-CHO treatment prevented formation of myo-
tubes compared to control and the combination of LIF
and Ac-DEVD-CHO also prevented formation of myo-
tubes (Figure 3A). Caspase-3 proteolytic activity was
significantly reduced with LIF treatment by a similar
proportion to that observed with immunocytochemical
detection of cleaved caspase-3 (Figure 3B). As expected
Ac-DEVD-CHO inhibited caspase-3 activity, but inter-
estingly the combination of LIF and Ac-DEVD-CHO did
not reduce caspase-3 activity more than LIF or Ac-
DEVD-CHO alone and therefore did not appear to be
Figure 3 Caspase-3 inhibition and LIF both inhibit myogenic
differentiation and caspase-3 activity. (A) Phase contrast images
of myoblast cultures either with or without 10 ng/mL LIF or 100 μM
Ac-DEVD-CHO (DEVD-CHO) treatment after 24 hours of
differentiation showed qualitatively less myotubes present with LIF
and Ac-DEVD-CHO and the combination of both compared to
control. (B) Colormetric assay for caspase-3 proteolytic activity in
cultures lysed 24 hours after differentiation. Caspase-3 activity is
reduced with LIF, Ac-DEVD-CHO and the combination of LIF and
Ac-DEVD-CHO. (C) Creatine kinase activity from the same lysates is
also decreased with LIF, Ac-DEVD-CHO and the combination of LIF
and Ac-DEVD-CHO indicating that inhibition of differentiation
correlates with inhibition of caspase-3 proteolytic activity. Asterisk (*)
indicates P < 0.05 and ns indicates P > 0.05 with one-way ANOVA
and Bonferroni’s post-hoc test for all treatments compared to each
other (n = 4).
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lysates and paralleled the change in caspase-3 activity
(Figure 3C). LIF and Ac-DEVD-CHO alone decreased
CK activity in the 24-hour differentiated cultures as did
the combined treatment. The combination of LIF and
Ac-DEVD-CHO also did not appear to have an additive
effect of reducing CK activity. These results are con-
sistent with the immunocytochemical analysis that
LIF inhibits caspase-3 activity during myogenic differen-
tiation, which parallels a reduction in measures of
differentiation.
LIF alters transcripts of myogenic regulators and prevents
decreases in proliferation caused by induction of
differentiation
Analysis using real-time qPCR of transcripts important
for myoblast differentiation showed an overall trend for
decreased levels of positive regulators of myogenesis
shortly after LIF treatment (Figure 4A). Transcripts for
the MRFs myogenin and myoD were decreased at t = 0,
which corresponds to 24 hours of LIF exposure and
before differentiation is induced, suggesting that LIF
decreases these messenger RNAs in the proliferating
myoblasts. There was no significant difference at t = 24
with LIF treatment (P >0 . 0 5 )f o rb o t hm y o g e n i na n d
myoD and at t = 48 these transcripts were significantly
up-regulated in the LIF-treated group (P <0 . 0 5f o rm y o -
genin and myoD). The cell cycle inhibitor p21 also
followed the same trend as myogenin and myoD with sig-
nificant decreases at t = 0, no significant difference at t =
24 and significantly increased at t = 48 with LIF treat-
ment. The overall trend for these positive regulators of
myogenesis, with a rightward shift on the time axis,
suggests that LIF treatment causes a temporary down-
regulation of these transcripts which is later negated,
with no significant difference at t = 24, and even com-
pensated for as differentiation proceeded (significantly
up-regulated at t = 48). Expression of c-fos, which is an
immediate early gene that can negatively regulate differ-
entiation of myoblasts through repression of myogenin
and myoD [17,18], was significantly increased with LIF
treatment at t = 0 and t = 24, but not significantly differ-
ent at t = 48 and t = 72. To further investigate whether
inhibition of myogenic differentiation could be due to
LIF inducing proliferation, as has been suggested pre-
viously [11,19], we examined proliferation and differen-
tiation simultaneously following LIF treatment via
immunofluoresence utilizing bromodeoxyuridine (BrdU)
incorporation in DNA synthesizing cells and desmin
to derive a fusion index of differentiated cells (Figure 4B).
Figure 4 LIF alters transcripts of genes relevant to myogenic differentiation and cell cycle progression and prevents decreases in
proliferation due to differentiation. (A) Real-time qPCR to determine relative mRNA quantity of the genes for myogenin, myoD, p21 and c-fos
comparing LIF-treated to control over 72 hours of differentiation. Asterisk (*) indicates P < 0.05 by pair wise fixed reallocation randomization tests
with REST for LIF- treated compared to control at that specific time point (n = 4). (B) Dual immunofluorescently labelled myogenic cultures for
incorporated BrdU and desmin from 0 to 48 hours after differentiation were counted and represented as a percentage of total cells positive for
incorporated BrdU and fusion index (percentage of nuclei contained within desmin positive syncytia). Asterisk (*) indicates P < 0.05 with
Student’s t-test for LIF compared to control at that time point (n = 4).
Hunt et al. Skeletal Muscle 2011, 1:17
http://www.skeletalmusclejournal.com/content/1/1/17
Page 5 of 13BrdU incorporation and thus DNA synthesis had
occurred in 30% of cells before differentiation was
induced (t = 0) which decreased to 12% 24 hours after
differentiation had been induced (t = 24) and remained
at that level until differentiation had reached a maximum
(t = 48) in the control group. LIF exposure for 24 hours
(t = 0) did not directly increase the percentage of myo-
blasts positive for BrdU incorporation suggesting LIF
does not directly induce proliferation. This is more con-
sistent with recent studies [14,20]. However the decreases
in BrdU positive cells that occurred after 24 hours of dif-
ferentiation in the control group did not occur with LIF
treatment until t = 48 when LIF-treated cultures showed
t h es a m ed e g r e eo fd i f f e r e n t i a t i o na sc o n t r o lc u l t u r e s .
Overall these results may indicate that LIF inhibits cell
cycle withdrawal via transient up-regulation of c-fos
and down-regulation of the cdk inhibitor p21 which
maintains myoblasts in a proliferative state without
directly inducing proliferation and therefore inhibiting
differentiation temporarily.
LIF is found in growth media and regulates
differentiation and differentiation associated apoptosis
Although it is well established that myoblasts are sensitive
to LIF it is not well known whether myoblasts may be
responsible for the production and secretion of LIF as an
autocrine factor. Therefore we examined the regulation of
endogenous LIF during myogenesis in vitro.L I Ft r a n -
scripts, as measured by qPCR, were detected in mRNA
isolated from undifferentiated myoblasts as well as differ-
entiated cultures, with the greatest level of transcript pre-
sent at t = 24 (Figure 5), suggesting that LIF may be
produced in greatest quantity by myoblasts that are in the
process of differentiating. Somewhat paradoxically,
Figure 5 Expression of endogenous transcripts for LIF and receptor components and LIF protein in conditioned media during
differentiation. Real-time qPCR for transcripts of LIF, LIFR and gp130 showed increased LIF with a peak 24 hours after differentiation, decreased
LIFR following differentiation and relatively consistent levels of gp130 throughout differentiation. Western immunoblot showed the presence of
45 kDa glycoslyated LIF in the conditioned media (CM) comprised of growth media at t = 0 but not conditioned media comprised of
differentiation media t = 24 or t = 48 hours. The same 45 kDa band was observed in growth media (GM) but not differentiation media (DM)
that was not cultured with cells, that is non-conditioned media (NCM).
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protein, representing glycosylated LIF, could only be
detected in conditioned media (CM) taken from proliferat-
ing myoblasts (t = 0) and not after induction of differentia-
tion when transcripts were greatest. However, LIF was
detected in the growth media (GM) but not differentiation
media (DM) of non-conditioned media (NCM) that is
fresh media that was not cultured with cells. As t = 0 CM
consisted of cultured GM while t = 24 and t = 48 CM con-
sisted of cultured DM, the LIF protein detected in t = 0
CM is likely derived from the GM itself and so would
obscure detection of any endogenously produced LIF.
However we could not detect any LIF at t = 24 when tran-
scripts were greatest suggesting that the level of endogen-
ously produced LIF was too low to be detected. The only
difference between GM and DM is the type and percen-
tage of serum present, GM contains 10% fetal bovine
serum whereas DM contains 2% normal horse serum.
Therefore the LIF detected in GM and t = 0 CM is quite
likely to be bovine LIF present in the fetal bovine serum.
To determine if bovine LIF was affecting the differen-
tiation of myoblasts we employed the LIFR antagonist
MH35-BD, a mutant form of LIF that binds the LIFR
but does not elicit signalling to any great degree and is
therefore a competitive antagonist of LIF [21]. Myoblasts
were incubated with different concentrations of MH35-
BD in GM for the culture period 24 hours before differ-
entiation, then induced to differentiate with DM, and
differentiation and differentiation associated apoptosis
examined. CK activity at t = 24 was significantly
increased compared to control with MH35-BD exposure
at concentrations of 100 ng/mL and greater (Figure 6A),
suggesting that inhibition of bovine LIF promoted differ-
entiation. Similarly at t = 24 the percentage of active
caspase-3 and TUNEL positive cells was significantly
increased with 100 ng/mL MH35-BD (Figure 6B and
6C). Overall inhibition of LIF present in growth media
with 100 ng/mL MH35-BD, presumably bovine LIF,
increased CK activity and the percentage of active cas-
pase-3 and TUNEL positive cells by 27%, 34% and 30%,
respectively, above control levels. This suggests that
bovine LIF present in fetal bovine serum can indeed eli-
cit effects through the murine LIF receptor. We also
investigated the LIF receptor components LIFR and
gp130. Transcripts for LIFR decreased sharply following
differentiation while gp130 remained relatively consis-
tently expressed throughout (Figure 5).
Discussion
Given the numerous reports of the effect of LIF on
myoblasts [11,13,14,19,22,23] it is not surprising that
transcripts for LIFR and gp130 were detected in myo-
blasts in this study as they would be required for LIF to
elicit an effect. However it was interesting that LIFR
transcripts decreased after the induction of differentia-
tion suggesting desensitization to LIF stimulation in the
more differentiated cultures.
Figure 6 MH35-BD blocks the biological effect of LIF in growth
media showing increased differentiation and apoptotic signalling.
(A) Creatine kinase activity of myoblasts after 24 hours of differentiation
with increasing concentrations of MH35-BD; 100 ng/mL and 1000 ng/
mL MH35-BD significantly increased creatine kinase activity. Asterisk (*)
indicates P < 0.05 with one-way ANOVA and Dunnet’s post-hoc test for
all concentrations compared to control (n = 4). (B) The percentage of
cells positive for cleaved caspase-3 after 24 hours differentiation was
increased with MH35-BD (100 ng/mL) treatment. Asterisk (*) indicates P
<0 . 0 5w i t hS t u d e n t ’s t-test compared to control (n = 4). (C) The
percentage of cells positive for TUNEL after 24 hours of differentiation
was increased with MH35-BD (100 ng/mL) treatment. Asterisk (*)
indicates P <0 . 0 5w i t hS t u d e n t ’s t-test compared to control (n = 4).
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myoblasts secreted into conditioned media; however, we
d i df i n de v i d e n c ef o rt h ep r e s e n c eo fb o v i n eL I Fi n
growth media containing fetal bovine serum. Given that
bovine LIF possesses 77% amino acid sequence homol-
ogy to murine LIF and murine LIF is routinely used to
improve development of cultured bovine embryos
[24,25], indicating that the bovine LIF receptor is sensi-
tive to murine LIF, it would be believable that the mur-
ine LIF receptor is sensitive to bovine LIF. In our study
addition of the competitive LIFR antagonist MH35-BD
increased measures of differentiation and differentiation
associated apoptosis, the opposite effect of stimulation
with exogenous murine LIF, suggesting that bovine LIF
present in GM was inhibiting differentiation of myo-
blasts and this was inhibited by MH35-BD. Therefore
we hypothesize that the long held method for inducing
differentiation in vitro by switching from the growth
factor rich fetal bovine serum to low growth factor nor-
mal horse serum may act to induce differentiation at
least in part by removal of LIF as an inhibitor of myo-
genic differentiation and as one of many possible growth
factors present in relatively high levels in fetal bovine
serum.
Although changes in transcripts for LIF were observed
during differentiation we could not detect any endogen-
ously produced LIF secreted into conditioned media even
when transcripts were highest, suggesting that relatively
little LIF is produced by myoblasts under these conditions.
Consistent with this is that relatively large concentrations
(10 ng/mL) of exogenous LIF as well as an unknown
quantity of bovine LIF in growth media are required to
achieve a maximum effect of LIF inhibiting differentiation,
suggesting that the LIFR is under-saturated by any endo-
genous LIF produced by myoblasts. If myoblasts do not
produce significant amounts of LIF under these conditions
then it might insinuate that without stimuli additional to
what is provided in this study, myoblasts may not be the
major source of LIF in vivo observed to be up-regulated in
muscle injury [10] and might be due to other cells such as
macrophages, fibroblasts or neurons present in the muscle
tissue. A recent study utilizing a more sensitive ELISA
method for the detection of LIF has suggested that cul-
tured myotubes can produce approximately 3.5 pg/mL of
LIF into media, compared to approximately 0.8 pg/mL
found in the non-conditioned horse serum containing
differentiation media control [26]. This amount is approxi-
mately 1,000 fold less than is typically found to have an
effect on cells and would therefore support our supposi-
tion that myogenic cultures do not produce significant
amounts of LIF.
Earlier studies examining the effect of LIF on myogenic
differentiation suggested that LIF neither promoted nor
inhibited differentiation [23], but more recently it was
demonstrated that LIF inhibits myogenic differentiation
[11,22]. The present study confirms the most recent
reports that LIF does indeed inhibit myogenic differentia-
tion and provides a greater understanding of the mechan-
isms underlying this effect and additional insight into the
involvement of LIF in differentiation-associated apoptosis
as well as the regulation of LIF and receptor components
during myogenesis. PI3K signalling promotes myogenic
differentiation [27] and mediates LIF dependent inhibition
of apoptosis in myoblasts [14]. In the present study inhibi-
tion of the PI3K pathway significantly reduced fusion
index but did not prevent LIF-dependent decreases in
caspase-3 activation indicating that this inhibition of
caspase-3 activation was not PI3K mediated. LIF appeared
to inhibit differentiation and caspase-3 activation by a
MEK and extracellular signal-regulated kinase (ERK)
dependent mechanism. An example of how the MEK/ERK
pathway might influence caspase-3 activity is demon-
strated by ERK phosphorylation of caspase-9 at Thr-125,
which inhibits caspase-3 cleavage and activation [28].
Therefore we may speculate that activation of MEK by LIF
and subsequent inhibition of caspase-3 activation may be
directly responsible for the inhibition of differentiation
observed. Consistent with the observation that knockout
of caspase-3 in myoblasts inhibits myogenic differentiation
[8], we observed that the reversible caspase-3 inhibitor Ac-
DEVD-CHO inhibited myogenic differentiation. We also
observed active caspase-3 positive myoblasts that did not
show classical apoptotic morphology which supports
the notion that caspase-3 is associated with myogenic
differentiation and not only apoptosis.
Inhibition of caspase-3 activity with Ac-DEVD-CHO
achieved the same effect as LIF with inhibition of myo-
tube formation and CK activity reduced by a very similar
amount. Interestingly the combination of LIF and Ac-
DEVD-CHO did not further decrease caspase-3 or CK
activity compared to either treatment alone. One might
have expected that if LIF were to only inhibit the cleavage
of caspase-3 in 50% of cells (possibly due to ERK phos-
phorylation of caspase-9) as seen with immunocytochem-
ical analysis, the remaining cells that possessed active
caspase-3 would still have high caspase-3 proteolytic
activity that could be further inhibited. Treatment with
Ac-DEVD-CHO however did not achieve this, which
could suggest that LIF regulates proteins that inhibit not
just the cleavage of caspase-3 but also proteolysis at the
active site such as X-linked inhibitor of apoptosis protein
(XIAP) that is shown to be up-regulated with LIF treat-
ment compared to without LIF treatment in apoptotic
cells [14]. It could also suggest that inhibition of caspase-
3 activity with Ac-DEVD-CHO had reached a plateau,
that is caspase-3 activity was inhibited to a maximum
amount achievable. Nevertheless the combination of
immunocytochemical and enzymatic assays strongly
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vation and proteolytic activity that is normally increased
with myogenic differentiation and that this correlates
with inhibition of myogenic differentiation.
Inhibition of caspase pathways via dominant negative
expression of death receptors DR5 and FADD decreases
myoD messenger [29] and may explain why LIF stimula-
tion was also accompanied by decreased levels of myoD
messenger in our study. Expression of c-fos is also nega-
tively associated with the transcriptional activity of myoD
and myogenin inhibiting CK transcription by these tran-
scription factors [18]. This agrees with our finding that
LIF up-regulates expression of the c-fos transcripts and
also decreases CK enzyme activity and inhibits differentia-
tion. As p21 expression is dependent on myoD expression
[5] it is not surprising that LIF exposure also down-
regulated p21 mRNA. Corresponding to this decrease in
cdk inhibitor p21, LIF exposure maintained myoblasts in a
proliferative state for a longer period of time despite
culture conditions promoting cell cycle withdrawal and
differentiation. Altogether this suggests that LIF inhibits
myogenic differentiation by multiple mechanisms that
include inhibition of caspase-3 activation possibly leading
to a decrease in levels of myoD and myogenin, up-
regulation of c-fos, which may lead to inhibition of the
transcriptional activity of myoD and myogenin, and down-
regulation of p21 leading to delayed cell cycle withdrawal.
In addition to activation of caspase-3, LIF also inhibited
DNA fragmentation in populations of differentiating cells.
Although DNA fragmentation is classically associated with
a p o p t o s i si ti sa l s od e m o n s t rated that caspase-induced
DNA strand breaks can be important for the regulation of
differentiation. Caspase-activated DNAse (CAD) can be
activated by caspase-3 and allows for up-regulation of p21
to promote myogenic differentiation [30]. Therefore the
reduced DNA fragmentation observed with LIF treatment
may reflect the down-regulation of p21 and inhibition of
differentiation observed. DNA fragmentation within myo-
genic cells can occur in vivo and macrophage influx into
damaged muscle is temporally correlated with decreased
DNA fragmentation in myogenic cells [31]. As LIF is a
cytokine potentially secreted by macrophages in damaged
muscle [32] it could be suggested that LIF is but one such
secreted factor that may mediate this DNA fragmentation
in regenerating muscle tissue.
Conclusions
This study demonstrates for the first time the mechan-
isms involved in inhibition of myogenic differentiation by
LIF, in particular the importance of caspase-3 inhibition
as a mediator of inhibition of differentiation by LIF.
Although little is known about the effect of LIF on necro-
sis of muscle fibers, inflammation, innervation and other
factors important to skeletal muscle regeneration, this
study indicates a role for LIF on the myogenic cells
required for muscle regeneration, which may be to
prevent precocious differentiation.
Methods
Cell culture and reagents
C2C12 myoblast cells were obtained from Amercian Type
Culture Collection (ATCC; Manassas, VA, USA). Recombi-
nant murine LIF was purchased from Millipore (Billerica,
MA, USA). All reagents were obtained from Sigma-Aldrich
(Castle Hill, NSW, Australia) unless otherwise stated. For
all experiments comparing LIF-treated to -untreated myo-
blasts, myoblasts were seeded such that 24 hours prior to
induction of differentiation they were approximately
40-50% of total plate density and were incubated with
10 ng/mL LIF in growth media (10% fetal bovine serum in
DMEM) or growth media alone for 24 hours. Following
this, the cells, which were approximately 90% - 100% of
total plate density, were washed with PBS and differentia-
tion media (2% horse serum in DMEM) was added. Differ-
entiation media was replenished every 24 hours until the
end point of the experiment.
Protein expression and purification
The gene encoding the LIF mutant MH35-BD was sub-
cloned and expressed as a glutathione-S-transferase (GST)
fusion protein in Escherichia coli, strain BL21 using the
Overnight Express Autoinduction System (Novagen).
After 24 hours of incubation, the cells were harvested by
centrifuging at 10,000 rpm for 10 minutes at 4°C and the
pellet was stored at -20°C. Later, the pellet (approximately
40 g) was resuspended in 40 mL of freshly made buffer
(50 mM Tris-HCl pH 7.4, 500 mM NaCl, 1 mM Ethylene
diaminetetra acetatic acid, 1 mM Dithiothreitol, 1X pro-
tease inhibitor cocktail) and lysed by sonication. The cell
debris was then pelleted by centrifugation at 25,000 rpm
for 15 min at 4°C and the supernatant was filtered through
a 0.44 micron filter. The filtered supernatant was then
passed through a glutathione-agarose (Sigma-Aldrich,
Castle Hill, NSW, Australia) chromatography column
twice. Following this, the column was washed with 5 col-
umn volumes of the same buffer and incubated with
25 units of Thrombin (5 U of thrombin/mg of protein) for
2 days at room temperature (16 to 25°C). Thrombin was
added in order to cleave the protein from GST. For final
elution, the GST column was attached in series with a
benzamidine column, which traps thrombin thereby separ-
ating it from the purified protein in the eluate. The purity
of the protein was confirmed by SDS-PAGE and silver
staining.
MH35-BD bioactivity assay
To determine the biological activity of MH35-BD, a cell
proliferation assay employing Ba/F3-hLIF-R/hgp130 cells
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cell line derived from murine pro B lymphocytes, which
do not normally express LIF-R or gpl30 [33]. To generate
the stable Ba/F3-hLIF-R/hgp130 cell line, Ba/F3 cells were
stably transfected with the human LIF-R (hLIF-R) and
human gp130 (hgp130), after which they proliferated
rapidly in the presence of hLIF [34]. Their proliferation is
markedly decreased in the presence of hLIF antagonists.
The assay procedure was conducted as described pre-
viously [35].
Creatine kinase activity assay
C2C12s were cultured in 24-well plates until the end
point of the experiment. Cultures were then washed
twice with phosphate buffered saline (PBS) and lysed
with 150 μL lysis buffer containing 40 mM MES buffer
(2-(N-morpholino)ethanesulfonic acid), 50 mM Trizma
base, 1% (v/v) Triton X-100 and complete protease inhi-
bitor cocktail (1 tablet per 50 mL lysis buffer obtained
from Roche Applied Science (Castle Hill, NSW, Austra-
lia)). Insoluble material was pelleted by centrifugation
and the resulting supernatant was used for analysis of
creatine kinase (CK) activity. The supernatant (10 μL)
was added in triplicate for each sample to a 96-well
plate followed by 200 μL of CK-NAC (Thermo Scienti-
fic, Scoresby, VIC, Australia). The plate was then run on
a PARADIGM MicroPlate Detection Platform (Beckman
Coulter, Gladesville, NSW, Australia) set to 37°C and
the change in absorbance at 340 nm over 3 minutes
(20 second intervals) measured. The change in absor-
bance was converted to activity in units per liter (U/L)
by multiplication by the following factor k.
Normalizedexpression = (Ax)/(By)
W h e r eT Vi st h et o t a lr e a c t i o nv o l u m e( 0 . 2 1 0m L ) ,
A is the millimolar absorption coefficient of NADH at
340 nM (6.3), SV is the sample volume (0.010 mL) and
P is the pathlength of light (determined to be 0.533 cm
by spectrophotometric comparison of absorbances with
known pathlengths).
Caspase-3 colormetric proteolytic activity assay
All reagents for assessing caspase-3 activity including
Ac-DEVD-CHO were obtained from the Caspase-3
Assay Kit, Colormetric (Sigma Aldrich). C2C12s were
cultured in 12-well plates and treated as described in
‘Cell culture and reagents’.A tt h ee n dp o i n to ft h e
experiment cells were washed and lysed in 100 μLo f
l y s i sb u f f e rf r o mt h ek i ta n d8 0μLo ft h es a m p l ew a s
added to 10 μL of the 10× assay buffer and 10 μLo ft h e
2 mM Ac-DEVD-pNA chromogenic substrate into
96-well plates. They were incubated for 10 hours at
37°C after which the absorbance of the plates at 405 nm
was read. The absorbance was divided by the time in
minutes incubated in order to achieve the change absor-
bance units per minute. CK activity was also determined
as described above using 10 μL of the lysates.
Antibodies
Cleaved Caspase-3 (Asp175) (5A1E) Rabbit monoclonal
antibody was obtained from Cell Signalling Technology
(Danvers, MA, USA). Monoclonal Anti-Myosin MY-32
(Skeletal, Fast) antibody produced in mouse was
purchased from Sigma-Aldrich (Castle Hill, NSW,
Australia). Mouse anti-LIF (clone 2H2.2) was
purchased from Millipore (Billerica, MA, USA). Fluor-
escent secondary antibodies donkey anti-rabbit Alexa-
Fluor488, goat anti-mouse AlexaFluor594 and
streptavidin AlexaFluor594 were purchased from Invi-
trogen (Carlsbad, CA, USA). The secondary horserad-
ish peroxidise conjugated anti-mouse was purchased
from Cell Signalling Technology (Danvers, MA, USA).
Fluorescent immunocytochemistry
For dual labelling of caspase-3 and myosin heavy chain
(MYHC), cultures were fixed by adding a volume of 4%
paraformaldehyde (PFA) equal to the volume of media
present and incubated for 15 minutes. Following washing
with PBS, cultures were blocked with a solution contain-
ing 5% (v/v) donkey serum, 5% (v/v) goat serum and 0.3%
Triton X-100 in PBS for 60 minutes at room temperature
(RT). They were then incubated with 1/200 dilutions of
rabbit anti-cleaved caspase-3 and mouse anti-MYHC in
PBS overnight at 4°C. After washing with PBS, 1:250 dilu-
tions of the secondary antibodies donkey anti-rabbit
AlexFluor488 and goat anti-mouse AlexaFluor 594 in
PBS were added to the cultures and incubated for
45 minutes at RT. They were then counterstained with
4’,6-diamidino-2-phenylindole (DAPI) and mounted on
slides for imaging.
For dual labelling of bromodeoxyuridine (BrdU) incor-
porated cells and desmin BrdU cell proliferation, ELISA
kit (Roche Applied Science, Castle Hill, NSW, Australia)
was utilized following the recommended procedure up
until antibody incubations. Then, cultures were incubated
with the mouse anti-BrdU and rabbit anti-desmin antibo-
dies for 90 minutes at RT. They were washed and then
incubated with goat anti-mouse AlexaFluor594 and don-
key anti-rabbit AlexaFluor488 for 45 minutes at RT. They
were counterstained with DAPI and mounted on slides.
Slides were imaged on a Leica TCS SP2 confocal setup
(Leica Microsystems, Wetzlar, Germany) using photo-
multiplier tubes for absorption and emission spectra of
DAPI, AlexaFluor488 and AlexaFluor594 and imaged
sequentially to avoid bleed-through from overlapping
spectra. Digital photographic images were taken and
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indexes were calculated as the proportion of nuclei con-
tained within syncytia (2 or more nuclei per cytoplasm)
compared to the total nuclei present within a field of
view. BrdU and active caspase-3 positive cells were cal-
culated as the percentage of positive compared to total
nuclei present in a field of view. A minimum of 1,000
nuclei from multiple fields of view were counted for all
replicates and the total of all fields of view calculated as
a percentage for that particular sample.
TUNEL staining
Immunofluorescent labelling of DNA fragmentation in
myoblasts was achieved using the DeadEnd™ Fluore-
metric TUNEL system from Promega (Madison, WI,
USA). In short, myoblasts were fixed with 4% PFA, per-
meabilised in PBS with 0.3% Triton X-100, and incu-
bated with fluorescein-12-dUTP and Terminal
Deoxynucleotidyl Transferase for 1 hour at 37°C. The
reaction was stopped and excess non-incorporated fluor-
escein-12-dUTP washed off and cultures counterstained
with DAPI before being mounted on slides and visua-
lized for fluorescent microscopy.
Western immunoblotting
For detection of LIF in conditioned media from cultures as
well as non-conditioned media, samples were incubated at
95°C for 5 minutes with an equal volume of a reducing gel
loading buffer containing 100 mM Tris pH 6.8, 2% (w/v)
SDS, 5% (v/v) b- mercaptoethanol, 15% (v/v) glycerol and
0.1% (w/v) bromophenol blue. The samples and molecular
weight marker SeeBlue
® Plus2 (Invitrogen, Carslbad, CA,
USA) were then resolved on a 12% (w/v) Tris buffered
polyacrylamide gel with a constant current of 30 mA for
approximately 2 hours. The resolved protein was trans-
ferred onto BioTrace™PVDF transfer membrane (Pall
Corporation, Melbourne, VIC, Australia) and blocked with
5% (w/v) skim milk in PBS with 0.1% Tween-20 overnight
at 4°C. They were then incubated with 1:500 dilution of
mouse anti-LIF antibody overnight at 4°C. The horserad-
ish peroxidise conjugated anti-mouse antibody was used
as a secondary and incubated for 1 hour at RT and then
washed off. The membrane was then incubated with
Amersham ECL™ Western Blotting detection reagents
and exposed with Amersham Hyperfilm ECL film, which
were both purchased from GE Healthcare Life Science
( R y d a l m e r e ,N S W ,A u s t r a l i a ) .
Quantitative PCR assay
Total RNA was extracted from cultures grown in 6-well
plates using the SV Total RNA Isolation System (Promega,
Madison, WI, USA). RNA (1 μg) from each sample was
used for reverse transcription with M-MLV Reverse Tran-
scriptase (Promega, Madison, WI, USA). The cDNA
synthesised was subjected to real-time quantitative PCR
using SYBR Green qPCR Supermix UDG (Invitrogen,
Carlsbad, CA, USA) on a Roche LightCycler 480 real-time
PCR unit. The derived cycle threshold (Ct) values were
analyzed using the relative expression software tool
(REST) [36] in order to determine statistical difference.
Data were expressed as the mean of normalized expression
in order to display linear levels of transcripts of interest
normalized to the housekeeper cyclophilin A, which was
the most adequate housekeeper as it possessed the least
variability across all samples compared to other house-
keepers tested including HPRT, GAPDH and b-actin
using the “Bestkeeper” excel based tool [37].
k = (TV × 1000)/(A × SV × P)
Where A is the efficiency of amplification of the
housekeeper, B is the efficiency of the gene of interest,
× is the housekeeper Ct and y is the gene of interest Ct.
Oligonucleotide sequences for all genes assessed are
shown in Table 1.
List of abbreviations
BP: blocking peptide; CAD: caspase-activated DNAse; CDK: cyclin dependent
kinase; CK: creatine kinase; CM: conditioned medium; DM: differentiating
medium; DR5: death receptor 5; EGF: epidermal growth factor; ERK:
extracellular signal-regulated kinase; FADD: Fas-associated protein with death
domain; FGF: fibroblast growth factor; GM: growth medium; LIF: leukemia
inhibitory factor; LIFR: leukemia inhibitor factor receptor; MRF: muscle
regulatory factor; MYHC: myosin heavy chain; MEK: mitogen activated
Table 1 List of oligonucleotide sequences used for real-time qPCR
Gene name Forward (5’-3’) Reverse (5’-3’)
c-fos atgggctctcctgtcaacac tgtcaccgtggggataaagt
cyclophilinA ggccgatgacgagccc tgtctttggaactttgtctgcaa
gp130 catagtcgtgcctgtgtgct gtgaccactgggcaatatga
LIF caagaatcaactggcacagc agtggggttcaggaccttct
LIFR agaagaactggctcccattg ggatgtcgtcccatttcact
MyoD tacagtggcgactcagatgc tagtaggcggtgtcgtagcc
Myogenin agtgaatgcaactcccacag acgatggacgtaagggagtg
p21 gcagaccagcctgacagattc ttcagggttttctcttgcagaag
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Page 11 of 13protein kinase and extracellular signal regulated kinase kinase;PI3K:
phosphotidylinositol-3 kinase; NCM: non-conditioned medium; TA: tibialis
anterior; TUNEL: terminal deoxynucleotidyl transferase mediated dUTP Nick
End Labeling; XIAP: X-linked inhibitor of apoptosis protein
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